| Literature DB >> 32754913 |
Guixiu Yuan1, Shiquan Cui1, Xuan Chen1, Haochang Song1, Cao Huang2, Jianbin Tong1, Zhentin Yuan1, Lin Yu1, Xinrui Xiong1, Jihe Zhao1, Bo Huang2, Qinxue Wu2, Yibo Zhou1, Gong Chen1, Hongxia Zhou1, Xu-Gang Xia1.
Abstract
Mutation of profilin 1 (PFN1) can cause amyotrophic lateral sclerosis (ALS). To assess how PFN1 mutation causes the disease, we created transgenic rats with human genomic DNA that harbors both the coding and the regulatory sequences of the human PFN1 gene. Selected transgenic lines expressed human PFN1 with or without the pathogenic mutation C71G at a moderate and a comparable level and in the similar pattern of spatial and temporal expression to rat endogenous PFN1. The artificial effects of arbitrary transgene expression commonly observed in cDNA transgenic animals were minimized in PFN1 transgenic rats. Expression of the mutant, but not the wild type, human PFN1 in rats recapitulated the cardinal features of ALS including the progressive loss of motor neurons and the subsequent denervation atrophy of skeletal muscles. Detergent-insoluble PFN1 inclusions were detected as the first pathology in otherwise asymptomatic transgenic rats expressing mutant human PFN1. The findings suggest that protein aggregation is involved in the neurodegeneration of ALS associated with PFN1 mutation. The resulting rat model is useful to mechanistic study on the ALS.Entities:
Keywords: ALS; PFN1; aggregation; neurodegeneration; rat
Mesh:
Substances:
Year: 2020 PMID: 32754913 PMCID: PMC8994973 DOI: 10.1111/jnc.15139
Source DB: PubMed Journal: J Neurochem ISSN: 0022-3042 Impact factor: 5.372